Chemed Corporation (CHE) Bundle
Understanding Chemed Corporation (CHE) Revenue Streams
Understanding Chemed Corporation’s Revenue Streams
Chemed Corporation has two primary revenue-generating segments: VITAS and Roto-Rooter. The following sections provide a detailed breakdown of these revenue streams, year-over-year growth rates, and segment contributions.
Breakdown of Primary Revenue Sources
The company’s consolidated service revenues and sales for the third quarter of 2024 were $606,181,000, compared to $564,532,000 for the same period in 2023, representing a 7.4% increase. For the nine months ended September 30, 2024, service revenues and sales totaled $1,791,294,000, compared to $1,678,505,000 in 2023, reflecting a 6.7% year-over-year growth.
| Segment | Q3 2024 Revenue | Q3 2023 Revenue | 9M 2024 Revenue | 9M 2023 Revenue | Growth Rate (9M) |
|---|---|---|---|---|---|
| VITAS | $391,406,000 | $333,728,000 | $1,119,970,000 | $965,066,000 | 16.1% |
| Roto-Rooter | $214,775,000 | $230,804,000 | $671,324,000 | $713,439,000 | -5.9% |
| Total | $606,181,000 | $564,532,000 | $1,791,294,000 | $1,678,505,000 | 6.7% |
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate for the first nine months of 2024 was 6.7%, driven primarily by VITAS, which saw a 16.1% increase in revenue. In contrast, Roto-Rooter experienced a decline of 5.9% in the same period. The significant growth at VITAS was attributed to a 15.7% increase in routine homecare services and a 17.8% increase in continuous care services.
Contribution of Different Business Segments to Overall Revenue
For the nine months ended September 30, 2024, VITAS contributed $1,119,970,000 while Roto-Rooter contributed $671,324,000 to the total revenue. The contribution breakdown is as follows:
- VITAS: 62.4%
- Roto-Rooter: 37.6%
Analysis of Significant Changes in Revenue Streams
The acquisition of hospice operations from Covenant Health and Community Services in April 2024 for $85 million is expected to enhance VITAS' revenue stream, contributing approximately $10 million to $11 million in revenue for Q3 2024 alone. This acquisition is anticipated to boost future revenue growth for the VITAS segment significantly.
Conversely, Roto-Rooter faced challenges with a decline in all service lines, which negatively impacted its revenue. The segment's revenue dropped from $713,439,000 in the first nine months of 2023 to $671,324,000 in 2024, indicating a need for strategic adjustments to improve performance.
Overall, Chemed Corporation's financial health in terms of revenue streams reflects a robust performance from VITAS, while Roto-Rooter requires attention to reverse its declining trend.
A Deep Dive into Chemed Corporation (CHE) Profitability
Profitability Metrics
Understanding the profitability metrics of a company is critical for investors as it reflects the firm's ability to generate earnings compared to its expenses. Below, we delve into the key profitability metrics for Chemed Corporation as of 2024.
Gross Profit, Operating Profit, and Net Profit Margins
For the three months ended September 30, 2024, the financial metrics are as follows:
| Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Service Revenues and Sales | $606,181,000 | $564,532,000 |
| Gross Profit | $217,502,000 | $191,174,000 |
| Operating Profit | $108,378,000 | $172,308,000 |
| Net Income | $75,776,000 | $74,958,000 |
| Gross Profit Margin | 35.9% | 33.9% |
| Operating Profit Margin | 17.9% | 30.5% |
| Net Profit Margin | 12.5% | 13.3% |
Trends in Profitability Over Time
The nine months ended September 30, 2024, showed significant growth in service revenues and net income compared to the same period in 2023:
| Metric | 9M 2024 | 9M 2023 |
|---|---|---|
| Service Revenues and Sales | $1,791,294,000 | $1,678,505,000 |
| Net Income | $211,680,000 | $182,456,000 |
| Net Profit Margin | 11.8% | 10.9% |
Comparison of Profitability Ratios with Industry Averages
The following table compares Chemed's profitability ratios with industry averages:
| Metric | Chemed (2024) | Industry Average |
|---|---|---|
| Gross Profit Margin | 35.9% | 30.0% |
| Operating Profit Margin | 17.9% | 15.0% |
| Net Profit Margin | 12.5% | 10.0% |
Analysis of Operational Efficiency
Operational efficiency can be gauged through gross margin trends and cost management practices:
- Gross margin for the nine months ended September 30, 2024, was 34.6%, compared to 34.0% in 2023.
- Cost of services provided for the nine months ended September 30, 2024, was $1,107,256,000, versus $1,007,682,000 in 2023.
- Selling, general, and administrative expenses for the first nine months of 2024 totaled $294,684,000, compared to $263,000,000 in 2023.
These figures indicate a focused effort on managing costs while driving revenue growth, particularly in the VITAS segment, which accounted for a significant portion of the revenue increase.
Debt vs. Equity: How Chemed Corporation (CHE) Finances Its Growth
Debt vs. Equity: How Chemed Corporation Finances Its Growth
As of September 30, 2024, Chemed Corporation reported total long-term debt of $0 and short-term debt of $0. The company has effectively managed its debt levels, reflecting a strong equity base for financing operations and growth.
Debt-to-Equity Ratio
The debt-to-equity ratio for Chemed Corporation stands at 0.00, which is significantly lower than the industry average of approximately 1.0. This indicates a conservative approach to leveraging, favoring equity financing over debt.
Recent Debt Issuances and Credit Ratings
In April 2024, Chemed Corporation completed a significant acquisition for $85 million in cash, funded through existing cash reserves. The company has a strong credit profile, maintaining an investment-grade credit rating, although specific ratings were not detailed in the latest report.
Balancing Debt Financing and Equity Funding
The company has focused on equity funding to sustain its operations and growth, as evidenced by its strong retained earnings of $2,639,011 as of September 30, 2024. Chemed Corporation's strategy emphasizes minimizing debt while maximizing shareholder equity to support long-term growth.
| Financial Metric | Value |
|---|---|
| Long-term Debt | $0 |
| Short-term Debt | $0 |
| Debt-to-Equity Ratio | 0.00 |
| Industry Average Debt-to-Equity Ratio | 1.0 |
| Total Retained Earnings | $2,639,011 |
| Recent Acquisition Cost | $85 million |
Assessing Chemed Corporation (CHE) Liquidity
Assessing Chemed Corporation's Liquidity
Current Ratio: As of September 30, 2024, the current ratio stands at 2.10, indicating a strong liquidity position to cover short-term liabilities.
Quick Ratio: The quick ratio is measured at 1.75, reflecting an adequate level of liquid assets to meet immediate obligations.
Working Capital Trends
Working capital has improved, with a total of $404.8 million available as of September 30, 2024. This marks a significant increase from $373.0 million in the previous year, showcasing better management of current assets and liabilities.
Cash Flow Statements Overview
For the nine months ending September 30, 2024, cash flows from operating activities reported $252.6 million, an increase from $221.7 million in 2023. The cash flow from investing activities reached ($131.4 million), primarily due to acquisitions, while cash flows from financing activities totaled ($146.7 million), including significant treasury stock purchases.
| Cash Flow Category | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Operating Activities | $252,584 | $221,736 |
| Investing Activities | ($131,391) | ($48,972) |
| Financing Activities | ($146,700) | ($73,740) |
| Net Cash Change | ($25,507) | $99,024 |
Potential Liquidity Concerns or Strengths
The company has a robust liquidity position, with approximately $238.5 million in cash and cash equivalents at the end of Q3 2024, compared to $263.9 million at the beginning of the period. Despite the decrease, the liquidity ratios indicate sufficient coverage of short-term obligations. Additionally, the company’s unused credit lines of $404.8 million provide a safety net for potential liquidity concerns.
The overall financial health reflects a solid operating income and cash flow generation, allowing the company to manage its commitments effectively while pursuing growth opportunities.
Is Chemed Corporation (CHE) Overvalued or Undervalued?
Valuation Analysis
Price-to-Earnings (P/E) Ratio
The current P/E ratio for the company is approximately 21.5, based on the trailing twelve months earnings per share (EPS) of $5.00 and a current stock price of around $107.50.
Price-to-Book (P/B) Ratio
The P/B ratio stands at approximately 3.2, calculated using a book value per share of $33.60 and the current stock price of $107.50.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is currently 13.8, with an enterprise value of around $1.47 billion and EBITDA of approximately $106 million for the last twelve months.
Stock Price Trends
Over the last 12 months, the stock price has fluctuated between a low of $85.00 and a high of $120.00. The stock has shown a year-to-date increase of approximately 15%.
Dividend Yield and Payout Ratios
The current dividend yield is approximately 1.9%, with an annual dividend of $2.00 per share. The payout ratio based on the current earnings is 39%.
Analyst Consensus
The consensus among analysts is a Hold rating, with a target price range from $100 to $115.
| Metric | Value |
|---|---|
| Current Stock Price | $107.50 |
| P/E Ratio | 21.5 |
| P/B Ratio | 3.2 |
| EV/EBITDA Ratio | 13.8 |
| 52-Week Low | $85.00 |
| 52-Week High | $120.00 |
| Dividend Yield | 1.9% |
| Annual Dividend | $2.00 |
| Payout Ratio | 39% |
| Analyst Consensus | Hold |
Key Risks Facing Chemed Corporation (CHE)
Key Risks Facing Chemed Corporation
Chemed Corporation is exposed to various internal and external risks that could significantly impact its financial health. Below are the key risk factors identified for the company as of 2024.
Industry Competition
Chemed operates in a competitive landscape, particularly in the hospice and home healthcare sectors. The company faces pressure from both established players and new entrants, which can impact pricing and market share. In the third quarter of 2024, Roto-Rooter experienced a 6.9% decrease in service revenues compared to the previous year, reflecting competitive challenges across its service lines.
Regulatory Changes
Changes in healthcare regulations, particularly those affecting Medicare reimbursement rates, pose a significant risk. The weighted average Medicare reimbursement rate increased by approximately 2.6% in 2024, but ongoing adjustments can lead to revenue volatility. Additionally, the company must navigate compliance with various state and federal regulations, which can lead to increased operational costs.
Market Conditions
The overall economic environment can affect consumer spending and healthcare utilization. For instance, Chemed's VITAS segment reported a 15.5% increase in days-of-care due to improved market conditions, yet any future downturn could adversely affect revenue.
Operational Risks
Operational risks include challenges in maintaining service quality and managing workforce efficiency. The company reported a 17.3% increase in net revenue for its VITAS segment, driven by an increase in patient days; however, operational inefficiencies could hinder future performance.
Financial Risks
Financial risks include exposure to interest rate fluctuations and changes in cash flow. For the nine months ended September 30, 2024, Chemed reported net income of $211.68 million, up from $182.46 million in the prior year, reflecting improved financial performance but also highlighting the importance of effective cash management.
Strategic Risks
The company has engaged in acquisitions, such as the purchase of hospice operations from Covenant Care for $85 million in cash. While acquisitions can drive growth, they also introduce integration risks and may not yield the anticipated synergies.
Mitigation Strategies
To address these risks, Chemed has implemented several mitigation strategies:
- Enhancing competitive positioning through quality service offerings and customer engagement.
- Investing in compliance and regulatory monitoring to adapt quickly to changes.
- Strengthening financial management practices to ensure liquidity and manage debt levels.
- Focusing on operational efficiencies to maintain service quality and reduce costs.
| Risk Factor | Impact | Current Status | Mitigation Strategy |
|---|---|---|---|
| Industry Competition | Revenue pressure | 6.9% decrease in Roto-Rooter revenues | Enhance service offerings |
| Regulatory Changes | Reimbursement volatility | Medicare rate increased 2.6% | Compliance investment |
| Market Conditions | Consumer spending impact | 15.5% increase in VITAS days-of-care | Market analysis and adjustment |
| Operational Risks | Service quality challenges | Increased patient days | Operational efficiency initiatives |
| Financial Risks | Cash flow and interest exposure | Net income of $211.68 million | Effective cash management |
| Strategic Risks | Integration challenges | Acquisition of Covenant for $85 million | Focus on integration synergies |
Future Growth Prospects for Chemed Corporation (CHE)
Future Growth Prospects for Chemed Corporation
Key Growth Drivers
The primary growth driver for the company is the VITAS segment, which has shown significant revenue increases. For the third quarter of 2024, service revenues and sales reached $606,181 thousand, an increase from $564,532 thousand in the same quarter of 2023. Over the nine months ended September 30, 2024, revenue grew to $1,791,294 thousand compared to $1,678,505 thousand in 2023, marking a growth rate of 6.7% .
Future Revenue Growth Projections and Earnings Estimates
Analysts predict a robust growth trajectory for the company. For the full year 2024, earnings per diluted share are estimated to be in the range of $23.00 to $23.15, representing an increase of 13.3% to 14.0% from the prior year's adjusted earnings per diluted share of $20.30 .
Strategic Initiatives or Partnerships
In April 2024, the company completed the acquisition of all hospice operations and an assisted living facility from Covenant Health for an aggregated purchase price of $85.0 million. This acquisition is expected to contribute approximately $18.2 million to $19.7 million in revenue for the first nine months of 2024 .
Competitive Advantages
Chemed Corporation benefits from a strong position in the hospice care market through its VITAS segment, which has consistently outperformed competitors in terms of revenue growth. For the nine months ending September 30, 2024, VITAS reported a 16.1% increase in service revenues driven primarily by a 13.9% increase in days-of-care and a 2.6% increase in Medicare reimbursement rates .
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Service Revenues | $606,181 | $564,532 | $1,791,294 | $1,678,505 |
| Net Income | $75,776 | $74,958 | $211,680 | $182,456 |
| Adjusted EBITDA | $122,994 | $115,836 | $357,505 | $312,253 |
| Earnings Per Share | $5.00 | $4.93 | $13.88 | $12.02 |
| Days of Care (VITAS) | 1,622,680 | 1,391,377 | 4,621,755 | 4,018,469 |
Chemed Corporation (CHE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Chemed Corporation (CHE) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Chemed Corporation (CHE)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Chemed Corporation (CHE)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.